Peter Hosein is an Oncology physician affiliated with University of Miami. OpenAlex indexes 190 publications with 3,775 citations (h-index 26); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1475 NW 12th Ave
Miami, FL 331361002
Telephone
305-243-5302Registry record last updated 7 Sept 2016.
Clinical trials
- The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
Sponsor: Benjamin Spieler
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20251 payment
- Caris MPI, Inc.Program year20252 payments
- Janssen Scientific Affairs, LLCProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
56.3%Antidiarrheal microorganisms30.5%Creon69%Zenpep31%Part D<11 patientsProton pump inhibitor11.4%Pantoprazole Sodium100%Part D≥15 patients+ 2 more classes in this area
Nervous system
26.1%Opioid Agonist11.7%Oxycodone-Acetaminophen60%Oxycodone Hcl40%Part D<11 patientsAtypical Antipsychotic4.7%Olanzapine100%Part D<11 patients+ 3 more classes in this area
Cardiovascular
7%Antiarrhythmic7%Lidocaine-Prilocaine54%Lidocaine46%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors
Journal for ImmunoTherapy of Cancer
2025 - Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer
JCO Precision Oncology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Myerburg, MD
University of Miami
Thomas Hooton, MD
University of Miami
Harry Flynn, MD
University of Miami
Alan Wein, MD
University of Miami
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”